What literature is there regarding experimental treatment of alveolar rhabdomyosarcoma?
Best insight from top research papers
Experimental treatment options for alveolar rhabdomyosarcoma (ARMS) have been explored in the literature. One study developed an organotypic model using a perfusion-based bioreactor to mimic key pathological features of invasive ARMS, such as cell-extracellular matrix interactions and tumor expansion . Another study investigated the combination of oncolytic virotherapy (OV) with a Janus kinase (JAK) inhibitor for the treatment of ARMS. The results showed that the combination therapy reduced clinical signs of disease and improved quality of life in mice with ARMS . Additionally, a pilot clinical study evaluated the activity of arsenic trioxide (ATO) combined with chemotherapy for the treatment of ARMS patients. The study found that the combined therapy exhibited beneficial activities against ARMS and was well tolerated . Furthermore, a case report discussed the treatment of an adult with nasal ARMS using chemotherapy and chemo-radiotherapy, based on protocols adapted from pediatric treatments . Lastly, a study developed a suicide gene therapy using an ARMS-targeted promoter to drive the herpes simplex virus thymidine kinase (HSV-TK) gene. The therapy effectively killed ARMS cells in vitro and in a xenograft mouse model, and when combined with standard chemotherapy agents, reduced the effective drug dose .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
3 Citations | The provided paper discusses a modified human MYOGENIN promoter that is highly active in alveolar rhabdomyosarcoma (ARMS) and could provide a new therapy option for this difficult-to-treat cancer. However, it does not provide information on other experimental treatments for ARMS. |
1 Citations | The provided paper does not specifically discuss experimental treatments for alveolar rhabdomyosarcoma. |
2 Citations | The provided paper discusses a pilot clinical study on the use of arsenic trioxide (ATO) combined with chemotherapy for the treatment of alveolar rhabdomyosarcoma (ARMS) in children. It reports positive outcomes and suggests the need for further large-scale clinical trials. However, it does not provide a comprehensive review of experimental treatments for ARMS. |
26 May 2020 | The provided paper discusses the experimental treatment of alveolar rhabdomyosarcoma using oncolytic virotherapy and a Janus kinase inhibitor. |
| The provided paper does not specifically discuss experimental treatment of alveolar rhabdomyosarcoma. |
Related Questions
What is best Treatment of angiosarcoma?5 answersThe best treatment for angiosarcoma involves a multidisciplinary approach due to its rarity and aggressive nature. Surgical resection with negative margins is the mainstay for localized disease, although achieving negative margins can be challenging. Adjuvant re-irradiation may enhance local control, but its impact on survival is uncertain. Systemic treatments show promise in both metastatic and neoadjuvant settings, with no established superior regimen due to high treatment heterogeneity. In cases of metastatic disease, chemotherapies like doxorubicin or weekly paclitaxel are common. Immunotherapy emerges as a promising avenue, but the lack of randomized studies hinders the establishment of a standard reference treatment. Overall, a tailored approach considering surgery, radiation, systemic therapies, and potentially immunotherapy is crucial for managing angiosarcoma effectively.
What is the prognosis of alveolar soft part sarcoma?5 answersThe prognosis of alveolar soft part sarcoma (ASPS) is characterized by its unique clinical features and outcomes. ASPS is a rare soft tissue sarcoma with an indolent clinical course but a high prevalence of metastases, particularly in the lung, liver, brain, and bone, even occurring more than a decade after the primary event. Patients with metastatic disease at presentation have a poorer prognosis, with a 5-year disease-specific survival rate of 62% compared to 86% for localized disease. Factors such as age, tumor size, primary site, and the presence of metastasis play crucial roles in prognostication. While postoperative adjuvant radiotherapy and chemotherapy do not provide significant benefits for localized ASPS cases, targeted therapy and immunosuppressive therapy show promise for advanced or metastatic disease, improving disease control rates. Overall, efforts are ongoing to develop novel therapeutic options for this challenging soft tissue sarcoma.
Are there any ongoing clinical trials immunotherapeutic strategies for the treatment of alveolar rhabdomyosarcoma?5 answersOngoing clinical trials are exploring immunotherapeutic strategies for alveolar rhabdomyosarcoma (ARMS). Research suggests that PAX3-FOXO1-expressing ARMS cells exhibit sensitivity to ATR inhibitors, leading to potential treatment avenues. Additionally, autoantibody profiling in ARMS patients has identified fibroblast growth factor 8 (FGF8) as a tumor antigen with diagnostic, prognostic, and therapeutic potential, highlighting the role of natural markers in unveiling novel targets for therapy. Immunotherapy, including immune checkpoint inhibitors, vaccines, and adoptive cell therapy, is being investigated as a promising approach for advanced bone and soft-tissue sarcomas, with certain subtypes showing higher immunogenicity and better responses to checkpoint inhibitors. These findings underscore the ongoing efforts to harness immunotherapy in the treatment of ARMS through clinical trials and novel therapeutic strategies.
How do clinical trials for uterine sarcoma contribute to the development of new treatments and improve patient outcomes?5 answersClinical trials play a crucial role in advancing treatments for uterine sarcoma by exploring novel therapeutic strategies. Studies have shown that enrollment in biomarker-matched early-phase trials leads to improved outcomes in heavily pretreated patients with metastatic sarcoma, including uterine leiomyosarcoma. Additionally, ongoing research focuses on targeting DNA damage repair pathways and immunosuppressive macrophage populations in advanced uterine leiomyosarcoma, reflecting the evolving understanding of uterine sarcoma biology. Furthermore, patient education tools, such as decision-aids and informative videos, have been successfully implemented to enhance patient understanding of clinical trial information, potentially improving patient experiences and outcomes in sarcoma trials. Overall, these trials not only drive the development of new treatments but also contribute to enhancing patient outcomes in the challenging landscape of uterine sarcoma treatment.
What are the recent clinical trial results in the treatment of uterine sarcoma?5 answersRecent clinical trial results in the treatment of uterine sarcoma have shown promising advancements. Studies have highlighted the effectiveness of various treatment modalities. For advanced uterine leiomyosarcoma, targeting DNA damage repair pathways and depleting immunosuppressive macrophage populations have shown potential benefits. Additionally, neoadjuvant chemotherapy and local radiotherapy have demonstrated favorable outcomes for patients with earlier stages of distant relapsed uterine leiomyosarcoma. Furthermore, fertility-sparing treatments have been explored in selected cases of early-stage uterine sarcoma, with conservative approaches leading to successful pregnancies in 32% of cases. These findings underscore the importance of ongoing research and the need for prospective clinical trials to translate molecular discoveries into effective therapeutic strategies for patients with uterine sarcomas.
Which kind of optimal treatment is there for patients with alveolar rhabdomyosarcoma?4 answersOptimal treatment for patients with alveolar rhabdomyosarcoma (ARMS) involves a multidisciplinary approach, including surgery, radiotherapy, and chemotherapy. In the course of ARMS, changes may be present in signaling pathways, including the RAS-PI3K pathway, Wnt/b-catenin pathway, receptor tyrosine kinase pathways, and myogenesis regulation. However, despite intensive treatment, the 5-year survival index for ARMS is not greater than 50%. A study has shown that ARMS cells expressing the PAX3-FOXO1 fusion oncogene are sensitive to pharmacological ataxia telangiectasia and Rad3 related protein (ATR) inhibition. ATR inhibitor treatment increases sensitivity of ARMS cells to PARP1 inhibition, and combined treatment with ATR and PARP1 inhibitors induces complete regression of primary patient-derived ARMS xenografts in vivo. These findings provide a rationale for upcoming biomarker-driven clinical trials of ATR inhibitors in patients suffering from ARMS.